Resalis Therapeutics is headquartered in Turin, Italy, with scientific roots originating from Aalborg University in Denmark and Harvard Medical School in the U.S. The company has elucidated the central role of a microRNA miR-22, which has a range of functions at the intersection of the molecular pathways underlining metabolic disorders.
Lead Program – RES-010
The company’s lead candidate, RES-010, is an antisense oligonucleotide designed to specifically target and inhibit miR-22. Resalis is developing RES-010, a novel treatment for obesity and fatty liver disease.
With its lead program, Resalis is opening a new therapeutic opportunity as a stand-alone treatment for obesity or to synergize with the current standard of care mechanisms of action (MoA) in combination. With RES-010’s unique MoA, the company plans to expand its potential as a therapeutic for metabolic associated fatty liver disease (MAFLD) and metabolic associated steatohepatitis (MASH), which are both indications with significant unmet medical need. While Resalis advances RES-010 through Phase 1 clinical evaluation, the company will continue to expand its pipeline.
Management Team and Board
Resalis’ management team and Board includes pioneers in RNA medicine and drug discovery and development leaders with many years of pharmaceutical industry and academic research experience.
